Aptevo Therapeutics Inc. (APVO) is a Seattle-based, clinical-stage biotechnology company developing immuno-oncology candidates built on its ADAPTIR and ADAPTIR-FLEX bispecific antibody platforms. The shares trade on the Nasdaq Capital Market as a true micro-cap, and the central question for investors is whether a stock priced near $1.24 can justify — let alone reach — the average analyst price target of $25.50.
Coverage of APVO is extremely sparse. Two analyst price targets are currently visible: Roth MKM's Jonathan Aschoff reiterated a Buy rating with a $21 target (maintained in August 2026 and cited again in September 2026), while a second, higher target sits at $30. The arithmetic mean of those two figures is $25.50, producing a target-to-price gap that looks dramatic precisely because the stock has fallen so far.
Importantly, these targets appear to lag the stock's collapse. Independent trackers have flagged that, after a roughly 95% decline over the past year, APVO's price targets "may not have had time to catch up." With only two data points spanning a wide $21-to-$30 range, this is best read as a loose indication of early analyst optimism rather than a hardened consensus.
The stock closed near $1.24 on November 6, 2026, toward the bottom of a 52-week range of $1.07 to $28.08. Reaching $25.50 would therefore require a gain of approximately 1,956% — a very large move that is not consistent with the company's current fundamentals. Aptevo is pre-revenue and reports negative EPS (earnings per share), and its market value sits in the low single-digit millions of dollars.
The company executed a 1-for-18 reverse stock split effective late December 2025 to support Nasdaq listing compliance, yet the shares have continued to slide. Any path toward a higher price would almost certainly depend on a series of positive clinical catalysts and a fundamentally re-rated valuation, rather than gradual earnings growth, because there is essentially no revenue base today.
The 52-week low of $1.07 and the psychological $1.00 level form the nearest support zone. Overhead, the 50-day moving average near $1.74 and the 200-day moving average near $4.17 represent resistance levels well above the current price, with a prior August consolidation area near $2.81 in between. The 52-week high of $28.08 sits just above the $25.50 target, underscoring how far the stock has retreated from its prior valuation.
Analyst price targets typically reflect a research horizon of about 12 months, though the thin coverage here provides little clarity on individual assumptions. Investors should watch cash-runway disclosures, quarterly results (the next report was estimated for around November 20, 2026), clinical data updates, any financing announcements, and Nasdaq compliance filings. Each of these can materially shift the outlook.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a thinly traded, high-volatility name such as APVO, automated signals can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review alone. Explore the AI Daily Buy/Sell Signals to see how the system currently reads the tape.
The $25.50 central target is the arithmetic mean of two analyst targets ($21 and $30) that appear to predate much of the stock's steep decline. Against a price near $1.24, the implied move of roughly 1,956% is very large and is not supported by current financials. The strongest supports are the clinical pipeline and platform technology, while the principal obstacles are persistent dilution, cash burn, listing-compliance risk, and the simple reality that these targets have likely not been recalibrated for the stock's collapse. Investors should monitor clinical data, financing activity, and Nasdaq compliance as the most relevant near-term signals.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, APVO has been closely correlated with GNPX. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if APVO jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To APVO | 1D Price Change % | ||
|---|---|---|---|---|
| APVO | 100% | -4.42% | ||
| GNPX - APVO | 92% Closely correlated | +1.46% | ||
| ICU - APVO | 92% Closely correlated | -3.06% | ||
| MLEC - APVO | 78% Closely correlated | N/A | ||
| NCEL - APVO | 50% Loosely correlated | +4.00% | ||
| NIKI - APVO | 46% Loosely correlated | -8.00% | ||
More | ||||